Aurinia Pharmaceuticals Inc. (AUPH) Given Outperform Rating at Leerink Swann
Leerink Swann restated their outperform rating on shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) in a report released on Monday morning. Leerink Swann currently has a $7.00 target price on the stock.
Other equities analysts have also issued reports about the stock. Canaccord Genuity set a $10.00 price target on shares of Aurinia Pharmaceuticals and gave the company a buy rating in a research report on Friday, August 5th. HC Wainwright assumed coverage on shares of Aurinia Pharmaceuticals in a research report on Thursday, June 30th. They set a buy rating and a $7.00 target price on the stock. Finally, FBR & Co reiterated an outperform rating and set a $9.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, August 15th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has an average rating of Buy and a consensus price target of $7.75.
Aurinia Pharmaceuticals (NASDAQ:AUPH) traded up 4.3056% during trading on Monday, reaching $3.3795. 542,728 shares of the company were exchanged. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $4.49. The firm’s market cap is $119.25 million. The firm has a 50-day moving average of $2.20 and a 200-day moving average of $2.74.
A hedge fund recently raised its stake in Aurinia Pharmaceuticals stock. Abingworth LLP raised its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 479.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 512,036 shares of the company’s stock after buying an additional 423,729 shares during the period. Aurinia Pharmaceuticals comprises 1.5% of Abingworth LLP’s portfolio, making the stock its 16th largest position. Abingworth LLP owned approximately 1.56% of Aurinia Pharmaceuticals worth $1,388,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 20.04% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.